Novavax Reacquires Estrasorb From King
This article was originally published in The Pink Sheet Daily
Executive Summary
The company gets back full rights to the topical estrogen emulsion and picks up 50 reps from King. The transaction stems from King’s decision to exit the women’s health market.
You may also be interested in...
Esprit To Market Estrogen Therapy Estrasorb In 2006
The company gains rights to Novavax' topical estrogen therapy Estrasorb after the failure of Novavax' copromotion deal with King.
Esprit To Market Estrogen Therapy Estrasorb In 2006
The company gains rights to Novavax' topical estrogen therapy Estrasorb after the failure of Novavax' copromotion deal with King.
King Names Markison President & CEO
Brian Markison was also elected to the company's board of directors. He joined King as chief operating officer in March, and was named acting president and CEO in May.